In the liver and adipose tissue, preclinical studies have shown that URAT1 inhibition ameliorates steatosis, insulin resistance, and mitochondrial dysfunction largely through reductions in oxidative stress, lipogenesis, and pro-inflammatory signaling [11]. The gene discussed is SLC22A12; the disease is steatosis.